Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded by Bank of America to Neutral

Bank of America upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRYFree Report) from an underperform rating to a neutral rating in a report published on Friday morning, MarketBeat Ratings reports.

Separately, The Goldman Sachs Group began coverage on shares of Bayer Aktiengesellschaft in a report on Thursday, May 30th. They set a neutral rating for the company. One investment analyst has rated the stock with a sell rating and nine have issued a hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Hold.

View Our Latest Stock Analysis on Bayer Aktiengesellschaft

Bayer Aktiengesellschaft Trading Down 0.8 %

Bayer Aktiengesellschaft stock opened at $7.95 on Friday. Bayer Aktiengesellschaft has a fifty-two week low of $6.82 and a fifty-two week high of $13.82. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.27. The firm’s fifty day moving average price is $7.42 and its 200-day moving average price is $7.43.

Bayer Aktiengesellschaft (OTCMKTS:BAYRYGet Free Report) last released its earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.25. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. The company had revenue of $12 billion during the quarter. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.38 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

(Get Free Report)

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

Further Reading

Analyst Recommendations for Bayer Aktiengesellschaft (OTCMKTS:BAYRY)

Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.